Recent Mercurio Lab work was a part of two presentations at the annual American Association for Cancer Research meeting.
Graduate student Emmet Karner presented on ferroptosis resistance in epithelial populations of TNBCs mediated by laminin 332 and integrin beta4. His abstract can be found here.
aTyr Pharma presented on our collaborative work highlighting a fully humanized monoclonal antibody targeting the VEGF-NRP2 pathway sensitizing highly aggressive and chemoresistant TNBC subtypes to chemotherapy. Their abstract can be found here.